Tumor lysate-loaded biodegradable microparticles as cancer vaccines

References

• Van Der Bruggen P, Traversari C, Chomez P et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254(5038), 1643–1647 (1991).
   PubMed Web of Science ®Google Scholar
• Boon T, Coulie PG, Van Den Eynde BJ, Van Der Bruggen P. Human T cell responses against melanoma. Annu. Rev. Immunol. 24, 175–208 (2006).
   PubMed Web of Science ®Google Scholar
• Dudley ME, Wunderlich JR, Robbins PF et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298(5594), 850–854 (2002).
   PubMed Web of Science ®Google Scholar
• Mcneel DG, Dunphy EJ, Davies JG et al. Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J. Clin. Oncol. 27(25), 4047–4054 (2009).
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9(3), 162–174 (2009).
   PubMed Web of Science ®Google Scholar
• Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol. 6(4), 295–307 (2006).
   PubMed Web of Science ®Google Scholar
• Galdiero MR, Garlanda C, Jaillon S, Marone G, Mantovani A. Tumor associated macrophages and neutrophils in tumor progression. J. Cell. Physiol. 228(7), 1404–1412 (2012).
   Web of Science ®Google Scholar
• Norian LA, Rodriguez PC, O'Mara LA et al. Tumor-infiltrating regulatory dendritic cells inhibit CD8+ T cell function via L-arginine metabolism. Cancer Res. 69(7), 3086–3094 (2009).
   PubMed Web of Science ®Google Scholar
• Le DT, Jaffee EM. Next-generation cancer vaccine approaches: integrating lessons learned from current successes with promising biotechnologic advances. J. Natl Compr. Cancer Netw. 11(7), 766–772 (2013).
   PubMed Web of Science ®Google Scholar
• Neumann E, Engelsberg A, Decker J et al. Heterogeneous expression of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: candidates for T-cell-based immunotherapies? Cancer Res. 58(18), 4090–4095 (1998).
   PubMed Web of Science ®Google Scholar
• Neller MA, Lopez JA, Schmidt CW. Antigens for cancer immunotherapy. Semin. Immunol. 20(5), 286–295 (2008).
   PubMed Web of Science ®Google Scholar
• De Gruijl TD, Van Den Eertwegh AJ, Pinedo HM, Scheper RJ. Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines. Cancer Immunol. Immunother. 57(10), 1569–1577 (2008).
   PubMed Web of Science ®Google Scholar
• Babu R, Adamson DC. Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-positive glioblastoma. Core Evid. 7, 93–103 (2012).
   PubMedGoogle Scholar
• Sanchez-Perez L, Kottke T, Diaz RM et al. Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo. Cancer Res. 65(5), 2009–2017 (2005).
   PubMed Web of Science ®Google Scholar
• Riker A, Cormier J, Panelli M et al. Immune selection after antigen-specific immunotherapy of melanoma. Surgery 126(2), 112–120 (1999).
   PubMed Web of Science ®Google Scholar
• Yu JS, Liu G, Ying H, Yong WH, Black KL, Wheeler CJ. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res. 64(14), 4973–4979 (2004).
   PubMed Web of Science ®Google Scholar
• Wheeler CJ, Black KL, Liu G et al. Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res. 68(14), 5955–5964 (2008).
   PubMed Web of Science ®Google Scholar
• Prins RM, Wang X, Soto H et al. Comparison of glioma-associated antigen peptide-loaded versus autologous tumor lysate-loaded dendritic cell vaccination in malignant glioma patients. J. Immunother. 36(2), 152–157 (2013).
   PubMed Web of Science ®Google Scholar
• Schaefer C, Butterfield LH, Lee S et al. Function but not phenotype of melanoma peptide-specific CD8(+) T cells correlate with survival in a multiepitope peptide vaccine trial (ECOG 1696). Int. J. Cancer 131(4), 874–884 (2012).
   PubMed Web of Science ®Google Scholar
• Haanen JB, Baars A, Gomez R et al. Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients. Cancer Immunol. Immunother. 55(4), 451–458 (2006).
   PubMed Web of Science ®Google Scholar
• Weide B, Zelba H, Derhovanessian E et al. Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis. J. Clin. Oncol. 30(15), 1835–1841 (2012).
   PubMed Web of Science ®Google Scholar
• Karbach J, Gnjatic S, Bender A et al. Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA -51: association with survival. Int. J. Cancer 126(4), 909–918 (2010).
   PubMed Web of Science ®Google Scholar
• Schwartzentruber DJ, Lawson DH, Richards JM et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N. Engl. J. Med. 364(22), 2119–2127 (2011).
   PubMed Web of Science ®Google Scholar
• Mitchell MS, Kan-Mitchell J, Kempf RA, Harel W, Shau HY, Lind S. Active specific immunotherapy for melanoma: Phase I trial of allogeneic lysates and a novel adjuvant. Cancer Res. 48(20), 5883–5893 (1988).
   PubMed Web of Science ®Google Scholar
• Sondak VK, Sosman JA. Results of clinical trials with an allogeneic melanoma tumor cell lysate vaccine: Melacine((R)). Semin. Cancer Biol. 13(6), 409–415 (2003).
   PubMed Web of Science ®Google Scholar
• Petrovsky N, Aguilar JC. Vaccine adjuvants: current state and future trends. Immunol. Cell Biol. 82(5), 488–496 (2004).
   PubMed Web of Science ®Google Scholar
• Schnurr M, Galambos P, Scholz C et al. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines. Cancer Res. 61(17), 6445–6450 (2001).
   PubMed Web of Science ®Google Scholar
• Gitlitz BJ, Figlin RA, Pantuck AJ, Belldegrun AS. Dendritic cell-based immunotherapy of renal cell carcinoma. Curr. Urol. Rep. 2(1), 46–52 (2001).
   PubMedGoogle Scholar
• Parajuli P, Mathupala S, Sloan AE. Systematic comparison of dendritic cell-based immunotherapeutic strategies for malignant gliomas: in vitro induction of cytolytic and natural killer-like T cells. Neurosurgery 55(5), 1194–1204 (2004).
   PubMed Web of Science ®Google Scholar
• Win SJ, Mcmillan DG, Errington-Mais F et al. Enhancing the immunogenicity of tumour lysate-loaded dendritic cell vaccines by conjugation to virus-like particles. Br. J. Cancer 106(1), 92–98 (2012).
   PubMed Web of Science ®Google Scholar
• Prasad S, Cody V, Saucier-Sawyer JK et al. Polymer nanoparticles containing tumor lysates as antigen delivery vehicles for dendritic cell-based antitumor immunotherapy. Nanomedicine 7(1), 1–10 (2011).
   PubMed Web of Science ®Google Scholar
• Harding CV, Song R. Phagocytic processing of exogenous particulate antigens by macrophages for presentation by class I MHC molecules. J. Immunol. 153(11), 4925–4933 (1994).
   PubMed Web of Science ®Google Scholar
• Rice-Ficht AC, Arenas-Gamboa AM, Kahl-Mcdonagh MM, Ficht TA. Polymeric particles in vaccine delivery. Curr. Opin. Microbiol. 13(1), 106–112 (2010).
   PubMed Web of Science ®Google Scholar
• Krishnamachari Y, Geary SM, Lemke CD, Salem AK. Nanoparticle delivery systems in cancer vaccines. Pharm. Res. 28(2), 215–236 (2011).
   PubMed Web of Science ®Google Scholar
• Wagner H. The immunogenicity of CpG-antigen conjugates. Adv. Drug Deliv. Rev. 61(3), 243–247 (2009).
   PubMed Web of Science ®Google Scholar
• Jain A, Gulbake A, Shilpi S, Hurkat P, Jain SK. A new horizon in modifications of chitosan: syntheses and applications. Crit. Rev. Ther. Drug Carrier Syst. 30(2), 91–181 (2013).
   PubMed Web of Science ®Google Scholar
• Salem AK, Hung CF, Kim TW, Wu TC, Searson PC, Leong KW. Multi-component nanorods for vaccination applications. Nanotechnology 16(4), 484–487 (2005).
   Web of Science ®Google Scholar
• Xiang SD, Scholzen A, Minigo G et al. Pathogen recognition and development of particulate vaccines: does size matter? Methods 40(1), 1–9 (2006).
   PubMed Web of Science ®Google Scholar
• Hanlon DJ, Aldo PB, Devine L et al. Enhanced stimulation of anti-ovarian cancer CD8+ T cells by dendritic cells loaded with nanoparticle encapsulated tumor antigen. Am. J. Reprod. Immunol. 65(6), 597–609 (2011).
   PubMed Web of Science ®Google Scholar
• Yoshikawa T, Okada N, Tsujino M et al. Vaccine efficacy of fusogenic liposomes containing tumor cell-lysate against murine B16BL6 melanoma. Biol. Pharm. Bull. 29(1), 100–104 (2006).
   PubMed Web of Science ®Google Scholar
• Kapsenberg ML. Dendritic-cell control of pathogen-driven T-cell polarization. Nat. Rev. Immunol. 3(12), 984–993 (2003).
   PubMed Web of Science ®Google Scholar
• Hildner K, Edelson BT, Purtha WE et al. Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. Science 322(5904), 1097–1100 (2008).
   PubMed Web of Science ®Google Scholar
• Van Den Broeke LT, Daschbach E, Thomas EK, Andringa G, Berzofsky JA. Dendritic cell-induced activation of adaptive and innate antitumor immunity. J. Immunol. 171(11), 5842–5852 (2003).
   PubMed Web of Science ®Google Scholar
• Fuchs EJ, Matzinger P. Is cancer dangerous to the immune system? Semin. Immunol. 8(5), 271–280 (1996).
   PubMedGoogle Scholar
• Gordon S. Pattern recognition receptors: doubling up for the innate immune response. Cell 111(7), 927–930 (2002).
   PubMed Web of Science ®Google Scholar
• Gnjatic S, Sawhney NB, Bhardwaj N. Toll-like receptor agonists: are they good adjuvants? Cancer J. 16(4), 382–391 (2010).
   PubMed Web of Science ®Google Scholar
• Pashine A, Valiante NM, Ulmer JB. Targeting the innate immune response with improved vaccine adjuvants. Nat. Med. 11(4 Suppl.), S63–68 (2005).
   PubMed Web of Science ®Google Scholar
• Blander JM, Medzhitov R. Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature 440(7085), 808–812 (2006).
   PubMed Web of Science ®Google Scholar
• Keijzer C, Slutter B, Van Der Zee R, Jiskoot W, Van Eden W, Broere F. PLGA, PLGA-TMC and TMC-TPP nanoparticles differentially modulate the outcome of nasal vaccination by inducing tolerance or enhancing humoral immunity. PLoS ONE 6(11), e26684 (2011).
   PubMed Web of Science ®Google Scholar
• Krishnamachari Y, Salem AK. Innovative strategies for co-delivering antigens and CpG oligonucleotides. Adv. Drug Deliv. Rev. 61(3), 205–217 (2009).
   PubMed Web of Science ®Google Scholar
• Zhang XQ, Dahle CE, Baman NK, Rich N, Weiner GJ, Salem AK. Potent antigen-specific immune responses stimulated by codelivery of CpG ODN and antigens in degradable microparticles. J. Immunother. 30(5), 469–478 (2007).
   PubMed Web of Science ®Google Scholar
• Foged C, Hansen J, Agger EM. License to kill: Formulation requirements for optimal priming of CD8(+) CTL responses with particulate vaccine delivery systems. Eur. J. Pharm. Sci. 45(4), 482–491 (2012).
   PubMed Web of Science ®Google Scholar
• Colaco CA, Bailey CR, Walker KB, Keeble J. Heat shock proteins: stimulators of innate and acquired immunity. Biomed. Res. Int. 2013, 461230 (2013).
   PubMed Web of Science ®Google Scholar
• Beaudette TT, Bachelder EM, Cohen JA et al. In vivo studies on the effect of co-encapsulation of CpG DNA and antigen in acid-degradable microparticle vaccines. Mol. Pharm. 6(4), 1160–1169 (2009).
   PubMedGoogle Scholar
• Greenberg NM, Demayo F, Finegold MJ et al. Prostate cancer in a transgenic mouse. Proc. Natl Acad. Sci. USA 92(8), 3439–3443 (1995).
   PubMed Web of Science ®Google Scholar
• Mueller M, Reichardt W, Koerner J, Groettrup M. Coencapsulation of tumor lysate and CpG-ODN in PLGA-microspheres enables successful immunotherapy of prostate carcinoma in TRAMP mice. J. Control Release 162(1), 159–166 (2012).
   PubMed Web of Science ®Google Scholar
• Buteau C, Markovic SN, Celis E. Challenges in the development of effective peptide vaccines for cancer. Mayo Clin. Proc. 77(4), 339–349 (2002).
   PubMed Web of Science ®Google Scholar
• Goforth R, Salem AK, Zhu X et al. Immune stimulatory antigen loaded particles combined with depletion of regulatory T-cells induce potent tumor specific immunity in a mouse model of melanoma. Cancer Immunol. Immunother. 58(4), 517–530 (2009).
   PubMed Web of Science ®Google Scholar
• Steele TA. Chemotherapy-induced immunosuppression and reconstitution of immune function. Leukemia Res. 26(4), 411–414 (2002).
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat. Rev. Immunol. 8(1), 59–73 (2008).
   PubMed Web of Science ®Google Scholar
• Vincent J, Mignot G, Chalmin F et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 70(8), 3052–3061 (2010).
   PubMed Web of Science ®Google Scholar
• Ercolini AM, Ladle BH, Manning EA et al. Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J. Exp. Med. 201(10), 1591–1602 (2005).
   PubMed Web of Science ®Google Scholar
• Gazzaniga S, Bravo AI, Guglielmotti A et al. Targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and tumor growth in a human melanoma xenograft. J. Invest. Dermatol. 127(8), 2031–2041 (2007).
   PubMed Web of Science ®Google Scholar
• Geary SM, Lemke CD, Lubaroff DM, Salem AK. The combination of a low-dose chemotherapeutic agent, 5-Fluorouracil, and an adenoviral tumor vaccine has a synergistic benefit on survival in a tumor model system. PLoS ONE 8(6), e67904 (2013).
   Web of Science ®Google Scholar
• Mattarollo SR, Loi S, Duret H, Ma Y, Zitvogel L, Smyth MJ. Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors. Cancer Res. 71(14), 4809–4820 (2011).
   PubMed Web of Science ®Google Scholar
• Frazier JL, Han JE, Lim M, Olivi A. Immunotherapy combined with chemotherapy in the treatment of tumors. Neurosurg. Clin. North Am. 21(1), 187–194 (2010).
   PubMed Web of Science ®Google Scholar
• He Q, Li J, Yin W et al. Low-dose paclitaxel enhances the anti-tumor efficacy of GM-CSF surface-modified whole-tumor-cell vaccine in mouse model of prostate cancer. Cancer Immunol. Immunother. 60(5), 715–730 (2011).
   PubMed Web of Science ®Google Scholar